Other
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified: > Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes: > Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale > Other
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 3002.13.00.90
Unmixed Monoclonal Antibody Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for therapeutic use in cancer treatment. It falls under HTS 3002.13.0090 as an unmixed immunological product not put up in measured doses or retail packaging, directly involved in regulating immunological processes. This classification applies to bulk biotech-derived antibodies for further pharmaceutical processing.
Bulk Rituximab Immunological Product
Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells, used in lymphoma and autoimmune disease therapy. Classified under HTS 3002.13.0090 as an unmixed immunological product obtained via biotechnological processes, supplied in bulk for formulation. It regulates immunological processes as defined in chapter notes.
Unmixed Infliximab Biosimilar
Infliximab biosimilar is a monoclonal antibody binding TNF-alpha, used for inflammatory conditions like rheumatoid arthritis. HTS 3002.13.0090 covers it as an unmixed, biotech-derived immunological product not in retail form. It qualifies per chapter notes as a protein regulating immunological processes.
Bulk Trastuzumab Emtansine Conjugate
Trastuzumab emtansine is an antibody-drug conjugate (ADC) with monoclonal antibody linked to chemotherapy agent for HER2-positive breast cancer. Classifies as unmixed immunological product in HTS 3002.13.0090 per notes covering antibody conjugates. Bulk form excludes retail packaging.
Adalimumab High-Concentration Solution
Adalimumab is a fully human monoclonal antibody against TNF for autoimmune diseases like psoriasis. As an aqueous solution of unmixed product, it qualifies under HTS 3002.13.0090 per chapter notes treating dissolved unmixed products similarly. Bulk for further dilution.
Bulk Pembrolizumab
Pembrolizumab is a PD-1 inhibitor monoclonal antibody for immuno-oncology applications. Classifies in HTS 3002.13.0090 as unmixed biotech immunological product regulating immune checkpoint processes. Not for retail sale.
Nivolumab Drug Substance
Nivolumab drug substance is bulk PD-1 blocking antibody for melanoma and lung cancer therapy. HTS 3002.13.0090 for unmixed immunological products via biotech processes. Meets definition of antibody regulating immunology.
Cetuximab Bulk Active
Cetuximab targets EGFR for colorectal cancer treatment as monoclonal antibody. Unmixed form under HTS 3002.13.0090 as per immunological product notes. Biotechnologically produced.
Denosumab Drug Substance
Denosumab is RANKL inhibitor monoclonal antibody for osteoporosis and cancer bone metastases. HTS 3002.13.0090 unmixed immunological product. Bulk biotech supply.
Omalizumab Bulk
Omalizumab anti-IgE monoclonal antibody for severe asthma. Classifies HTS 3002.13.0090 unmixed per chapter notes. Regulates allergic immune responses.
Tocilizumab Concentrate
Tocilizumab IL-6 receptor antagonist monoclonal antibody for cytokine storm and arthritis. Unmixed HTS 3002.13.0090 immunological product.
Dupilumab Drug Substance
Dupilumab IL-4/IL-13 inhibitor for atopic dermatitis and asthma. Biotech unmixed immunological HTS 3002.13.0090.
Bulk Colony Stimulating Factor G-CSF
Filgrastim (G-CSF) recombinant protein stimulating neutrophil production post-chemotherapy. Chapter notes cover colony stimulating factors as immunological products in HTS 3002.13.0090 unmixed.
Recombinant Interleukin-2 (IL-2)
Recombinant human IL-2 is a cytokine growth factor stimulating T-cell proliferation for cancer immunotherapy. It is an unmixed immunological product under HTS 3002.13.0090, explicitly covered by chapter notes for interleukins regulating immune processes. Supplied in bulk for pharmaceutical compounding.
Interferon Beta-1a Bulk Preparation
Interferon beta-1a is a recombinant cytokine for multiple sclerosis treatment, modulating immune response. HTS 3002.13.0090 applies to this unmixed, biotechnological immunological product not in measured doses. Chapter notes specifically include interferons.